DCIS and LCIS: Are the Risk Factors for Developing In Situ Breast Cancer Different?

Cancers (Basel). 2023 Sep 2;15(17):4397. doi: 10.3390/cancers15174397.

Abstract

Ductal carcinoma in situ (DCIS) is widely accepted as a precursor of invasive ductal carcinoma (IDC). Lobular carcinoma in situ (LCIS) is considered a risk factor for invasive lobular carcinoma (ILC), and it is unclear whether LCIS is also a precursor. Therefore, it would be expected that similar risk factors predispose to both DCIS and IDC, but not necessarily LCIS and ILC. This study examined associations with risk factors using data from 3075 DCIS cases, 338 LCIS cases, and 1584 controls aged 35-60, recruited from the UK-based GLACIER and ICICLE case-control studies between 2007 and 2012. Analysis showed that breastfeeding in parous women was protective against DCIS and LCIS, which is consistent with research on invasive breast cancer (IBC). Additionally, long-term use of HRT in post-menopausal women increased the risk of DCIS and LCIS, with a stronger association in LCIS, similar to the association with ILC. Contrary to findings with IBC, parity and the number of births were not protective against DCIS or LCIS, while oral contraceptives showed an unexpected protective effect. These findings suggest both similarities and differences in risk factors for DCIS and LCIS compared to IBC and that there may be justification for increased breast surveillance in post-menopausal women taking long-term HRT.

Keywords: DCIS; HRT; LCIS; breast cancer; breastfeeding; case control; hormone replacement therapy; logistic regression; risk factor.

Grants and funding

The ICICLE and GLACIER studies were supported by Breast Cancer Now, Cancer Research UK and Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. Research received funding from Cancer Research UK for sample and data collection (CRUK/08/046).